Moderna Sees COVID-19 Vaccine Surplus By 2022 If Constraints Ease
US Asked To Lift DPA Restrictions
Moderna, GSK and Bharat Biotech point to technology transfer, material shortages and manufacturing expertise as factors constraining COVID-19 vaccine supplies, rather than intellectual property rights. Meanwhile, Moderna's CEO forecasts a surplus of these vaccines by 2022.
